July 16, 2026

Model Favors Septoplasty at 24 Months

A UK trial-based economic evaluation found uncertain cost-effectiveness at 12 months, but a model extrapolating outcomes to 24 months estimated a lower cost per quality-adjusted life year for immediate surgery.

Conexiant

July 13, 2026

Side Effects: Signals in Strange Places

From breathier speech to breastfeeding history, metamaterial eye coils, and antifibrotic GLP-1 effects in mice, this week’s studies remind us that the most interesting signal is often hiding somewhere clinicians were not looking.

Conexiant

June 22, 2026

Deprivation Tied to Lower HNC-Specific QOL

The differences were present before patients began any treatment, suggesting quality-of-life gaps may be established before therapy begins.

Conexiant

June 19, 2026

Most Miss Streamlined Neck Mass Dx Path

Same-visit biopsy and fewer empiric workup steps were linked to faster pathologic diagnosis in a retrospective analysis.

Conexiant

June 15, 2026

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.

Conexiant

June 05, 2026

Chemoimmunotherapy Linked to HNSCC Response

Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.

Conexiant

June 05, 2026

Sleep Study Cutoffs May Guide Discharge

Preoperative sleep study values may distinguish lower-risk children within a population for whom overnight admission is currently routine.

Conexiant

May 14, 2026

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

Conexiant

May 11, 2026

Automated Staining Aids Real-Time Tumor Calls

Automated frozen-section staining helped classify selected ambiguous tumors and margins in a single-center validation study.

Conexiant

May 08, 2026

A Smarter Screen for Sleep Apnea Stimulation

A four-factor staging system stratified response rates from 90.9% to 37.5% in a retrospective cohort study, although the model showed only moderate discrimination (C statistic, 0.68) and requires external validation

Conexiant